

40년 전통의 MENA 제약 제조 회사





40 MENA

이 제약 제조 회사는 요르단 암만에서 약 40년 전에 설립되었습니다. 70개 이상의 특허를 보유하며 혁신 분야에서 지역 벤치마크를 선도하고 있습니다.

이러한 혁신의 직접적인 결과로, 성숙한 기술 플랫폼을 독립적인 관리 및 자원을 갖춘 자회사로 분사하여 기존 제네릭 제약 산업에서 벗어나 사업을 다각화했습니다.

버티컬

1. 핵심 브랜드 제네릭 제약 사업.
2. 자회사를 통한 천연 제품.
3. 자회사를 통한 생명공학 진단.
4. 자회사를 통한 새로운 부형제 및 약물 전달 시스템.

제품

제품은 심혈관, 위장, 종추신경계, 항감염, 내분비, 근골격계, 호흡기, 산부인과 및 비뇨기, 면역계를 포함한 광범위한 치료 카테고리를 포괄합니다.

제약 비즈니스

소비자와 의료 전문가의 요구를 충족하는 200개 이상의 의약품을 제공합니다. 이러한 제품에는 정제, 캡슐, 좌약, 시럽, 혼탁액 등이 있으며, 우수 의약품 제조 및 품질 관리 기준(GMP)에 따라 제조됩니다. 이 회사는 제품의 ‘품질’이 우수하기 때문에 선도적인 제약 회사 중 하나가 될 수 있는 경쟁 우위를 가지고 있습니다.

천연 제품

표준화된 약용 식물 추출물로 식물 및 허브 의료 제품을 개발 및 생산하는 중동 최고의 회사 중 하나로, 전 세계 20개국 이상에서 사업을 운영하며 50개 이상의 천연 및 허브 혁신 제품을 제공하는 것으로 유명합니다.

생명공학

독점적인 생명공학 헬스케어 제품을 전문적으로 개발 및 생산하는 업체입니다.

TARGET PRICE

\$45,000,000

GROSS REVENUE

\$37,000,000

EBITDA

\$6,279,944

BUSINESS TYPE

제약

COUNTRY

Jordan

BUSINESS ID

L#20230509

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction.

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



WWW.MERGERSCORP.COM